title: [In vitro effects of hemocoagulase atrix and its effective components on blood coagulation of patients with bleeding disorders].
abstract: This study was aimed to investigate the pro coagulation effects of hemocoagulase atrix and its effective components (batroxobin and factor X activator) on plasma of normal subjects and patients with bleeding disorders and their mechanisms. Activated partial thromboplastin time (APTT) and prothrombin time (PT) were measured. The factor (F)X activation and thrombin generation were analyzed by using chromogenic substrate method. The results showed that the plasma APTT of normal subjects was shortened by hemocoagulase atrix, batroxobin and FX activator, and the effect of FX activator was found to be concentration-dependent (r = 0.889, P < 0.05). The prolonged APTT of plasma from patients with bleeding disorders could be corrected by hemocoagulase atrix, batroxobin and FX activator, but PT showed no great changes resulted from the treatments. FX activator could promote FX activation and thrombin generation, while neither hemocoagulase atrix nor batroxobin showed such abilities. It is concluded that hemocoagulase atrix promotes coagulation process, and corrects coagulation abnormalities in patients with bleeding disorders, its main component batroxobin directly acts on fibrinogen, and FX activator promotes thrombin generation through activating FX.
authors.affiliation: Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.
authors.forename: Rui-Juan
authors.initials: RJ
authors.lastname: Wang
authors.forename: Zhao-Yue
authors.initials: ZY
authors.lastname: Wang
authors.forename: Ming-Hua
authors.initials: MH
authors.lastname: Jiang
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Li-Juan
authors.initials: LJ
authors.lastname: Cao
authors.forename: Xiong-Hua
authors.initials: XH
authors.lastname: Sun
authors.forename: Jian
authors.initials: J
authors.lastname: Zhang
authors.forename: Xia
authors.initials: X
authors.lastname: Bai
authors.forename: Chang-Geng
authors.initials: CG
authors.lastname: Ruan
mesh_terms: D000328:Adult; D012103:Batroxobin / Q000494:pharmacology*; D001777:Blood Coagulation / Q000187:drug effects*; D001778:Blood Coagulation Disorders / Q000097:blood*; D016022:Case-Control Studies; D003546:Cysteine Endopeptidases / Q000494:pharmacology; D005170:Factor X / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000494:pharmacology; D010314:Partial Thromboplastin Time; D013917:Thrombin / Q000378:metabolism; D055815:Young Adult
chemical_list: D009363:Neoplasm Proteins; D005170:Factor X; D012103:Batroxobin; D013917:Thrombin; D003546:Cysteine Endopeptidases; C030910:cancer procoagulant